Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > July 25, 2025
Daily News
July 25, 2025
- MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Santen’s Glaucoma Drug, Taisho’s Insomnia Med Up for Panel Review on July 31
July 25, 2025
- Chugai to Build New Research Building to Strengthen Process Development
July 25, 2025
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Pfizer Japan Recalls Syphilis Drug over Particulate Contamination
July 25, 2025
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
- IQVIA, JFCR Cancer Institute Partner to Speed Clinical Trials in Japan
July 25, 2025
- Dust Mite Sublingual Immunotherapy Linked to Lower Antibiotic Use in Children
July 25, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…